Overview

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Status:
Recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

The study is designed as a multicenter, non-randomized, Phase II trial with one treatment arm. A total of 82 patients of both genders and older than 18 years with relapsed/refractory multiple myeloma are planned to be included in the study. After the first 6 patients will have finished the first treatment cycle of the induction phase the DMC will assess safety and tolerability of the treatment schedule and decide about the further continuation of the study.

Phase:

Phase 2

Details

Lead Sponsor:

GWT-TUD GmbH

Treatments:

BB 1101
Cyclophosphamide
Dexamethasone
Dexamethasone acetate
Glycine
Ixazomib
Pomalidomide
Thalidomide